Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 27;7(3):100430. doi: 10.1016/j.esmoop.2022.100430

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Survival outcomes for patients in this study, based on their exposure to antibiotics.

(A) Progression-free survival for 168 patients for whom times (or censored values) could be obtained. The number of patients at risk in each category is shown below the table. (B) Overall survival for 168 patients for whom times (or censored values) could be obtained. The number of patients at risk in each category is shown below the table.

Patients were divided into two categories based on whether they had received antibiotics or not during the 2 weeks before until 6 weeks after treatment with tyrosine kinase inhibitors commenced. Kaplan–Meier estimator graphs illustrate survival outcomes for patients who did not receive antibiotics (blue line) and patients who received antibiotics (red line). OS; overall survival; PFS; progression-free survival.